Skip to content

Utilization of the Mirror During Pelvic Exams

Utilization of the Mirror During Pelvic Exams: Does it Reduce Patient Vulnerability and Discomfort?

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03785548
Enrollment
147
Registered
2018-12-24
Start date
2019-04-15
Completion date
2020-07-01
Last updated
2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pelvic Exam

Brief summary

This is a prospective cohort study to determine if using a birthing mirror during the patient's pelvic examination decreases patients's degree of vulnerability and discomfort.

Detailed description

In Obstetrics and Gynecology and its gynecologic subspecialties, the pelvic examination is routine practice for screening and diagnostic purposes. Nevertheless, due to their intimate nature, pelvic examinations may result in loss of control, embarrassment, discomfort and anxiety. The mirror pelvic exam has been a proposed technique to decrease patient anxiety and improve comfort during an already uncomfortable examination. However, little research has focused on this modality to date. The purpose of this study is to investigate whether the mirror pelvic exam decreases the level of vulnerability and discomfort experienced during the pelvic examination.

Interventions

OTHERUsage of a mirror

using a mirror during the pelvic examination

Sponsors

TriHealth Inc.
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* New patients undergoing a pelvic exam performed by a physician at Cincinnati Urogynecology Associates, TriHealth

Exclusion criteria

* Existing patients * Unwillingness to participate in the study * Physical or mental impairment that would affect the subject's ability to visualize the mirror during examination or to complete questionnaires * Inability to understand English

Design outcomes

Primary

MeasureTime frameDescription
Group Difference in Visual Analog Scale (VAS) on Level of Vulnerability30 minutes after the pelvic examVAS on vulnerability level will be measured after the pelvic exam, and group difference after controlling for baseline vulnerability, will be calculated. The VAS is a validated 100 millimeter scale with 'no vulnerability' represented as 0 mm and 'very vulnerable' equating to 100 mm.
Group Difference in Visual Analog Scale (VAS) on Level of Pain/Discomfort30 minutes after the pelvic examVAS on discomfort level will be measured after the pelvic exam, and group difference after controlling for baseline discomfort level, will be calculated. The VAS is a validated 100 millimeter scale with 'no pain' represented as 0 mm and 'most pain' equating to 100 mm.

Countries

United States

Participant flow

Participants by arm

ArmCount
Mirror Group
This group of patients agree to have the mirror pelvic exam, and they will undergo routine pelvic examination by a physician with the usage of a mirror in the room. Usage of a mirror: using a mirror during the pelvic examination
71
No Mirror Group
This group of patients decline a mirror, and they will undergo the standard pelvic examination.
74
Total145

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall Studyage > 8010
Overall Studyno Postop queries10

Baseline characteristics

CharacteristicMirror GroupNo Mirror GroupTotal
Age, Continuous53.99 years
STANDARD_DEVIATION 12.96
57.84 years
STANDARD_DEVIATION 13.86
55.95 years
STANDARD_DEVIATION 13.52
Race/Ethnicity, Customized
American Indian/Alaska Native
2 Participants0 Participants2 Participants
Race/Ethnicity, Customized
Asian
1 Participants0 Participants1 Participants
Race/Ethnicity, Customized
Black or African American
10 Participants5 Participants15 Participants
Race/Ethnicity, Customized
missing
0 Participants1 Participants1 Participants
Race/Ethnicity, Customized
Prefer not to answer
0 Participants2 Participants2 Participants
Race/Ethnicity, Customized
White
62 Participants66 Participants128 Participants
Region of Enrollment
United States
71 participants74 participants145 participants
Sex: Female, Male
Female
71 Participants74 Participants145 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 710 / 74
other
Total, other adverse events
0 / 710 / 74
serious
Total, serious adverse events
0 / 710 / 74

Outcome results

Primary

Group Difference in Visual Analog Scale (VAS) on Level of Pain/Discomfort

VAS on discomfort level will be measured after the pelvic exam, and group difference after controlling for baseline discomfort level, will be calculated. The VAS is a validated 100 millimeter scale with 'no pain' represented as 0 mm and 'most pain' equating to 100 mm.

Time frame: 30 minutes after the pelvic exam

Population: Each group has 1 missing outcome.

ArmMeasureValue (MEAN)Dispersion
Mirror GroupGroup Difference in Visual Analog Scale (VAS) on Level of Pain/Discomfort19.683 mmStandard Error 2.201
No Mirror GroupGroup Difference in Visual Analog Scale (VAS) on Level of Pain/Discomfort19.824 mmStandard Error 2.154
p-value: 0.96495% CI: [-5.983, 6.266]ANCOVA
Primary

Group Difference in Visual Analog Scale (VAS) on Level of Vulnerability

VAS on vulnerability level will be measured after the pelvic exam, and group difference after controlling for baseline vulnerability, will be calculated. The VAS is a validated 100 millimeter scale with 'no vulnerability' represented as 0 mm and 'very vulnerable' equating to 100 mm.

Time frame: 30 minutes after the pelvic exam

Population: There are 2 missing outcomes from Mirror group

ArmMeasureValue (MEAN)Dispersion
Mirror GroupGroup Difference in Visual Analog Scale (VAS) on Level of Vulnerability13.294 mmStandard Error 1.854
No Mirror GroupGroup Difference in Visual Analog Scale (VAS) on Level of Vulnerability16.145 mmStandard Error 1.789
p-value: 0.2795% CI: [-2.241, 7.944]ANCOVA

Source: ClinicalTrials.gov · Data processed: Feb 16, 2026